Marksans Pharma declines after US FDA issues Form 483 with 5 observations to Goan plant

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

Tuesday, April 30, 2024

Asian Paints

2877.05

(0.31%)

Axis Bank

1166.15

(0.58%)

Bajaj Finance

6931.05

(1.52%)

Bajaj Finserv

1615.70

(1.27%)

Bharti Airtel

1322.85

(-0.78%)

HCL Technologi..

1367.55

(-1.41%)

HDFC Bank

1517.05

(-0.77%)

Hind. Unilever

2230.70

(0.17%)

ICICI Bank

1152.05

(-0.58%)

IndusInd Bank

1515.60

(1.87%)

Infosys

1421.10

(-0.97%)

ITC

435.60

(-0.55%)

JSW Steel

882.60

(-1.50%)

Kotak Mah. Ban..

1623.75

(-1.01%)

Larsen & Toubr..

3594.15

(-1.09%)

M & M

2156.30

(4.53%)

Maruti Suzuki

12806.45

(0.87%)

Nestle India

2506.05

(-0.18%)

NTPC

363.10

(0.00%)

Power Grid Cor..

301.65

(2.71%)

Reliance Indus..

2931.15

(0.02%)

St Bk of India

825.70

(-0.05%)

Sun Pharma.Ind..

1502.30

(-1.29%)

Tata Motors

1007.85

(0.74%)

Tata Steel

164.95

(-1.46%)

TCS

3822.60

(-1.24%)

Tech Mahindra

1261.95

(-2.08%)

Titan Company

3589.15

(-0.44%)

UltraTech Cem.

9966.75

(0.05%)

Wipro

462.30

(-0.14%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Marksans Pharma declines after US FDA issues Form 483 with 5 observations to Goan plant	Share Back
(18 Apr 2024)
The US drug regulator had conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of the company located in Vema, Goa, India, from 9 April 2024 to 17 April 2024. On conclusion of the inspection, the company has received 5 inspectional observations in Form 483. There is no data integrity observation. 'The company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time,” Marksans Pharma said in a statement. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The company’s consolidated net profit jumped 33.69% to Rs 83.29 crore in Q3 FY24 as compared with Rs 62.30 crore in Q3 FY23. Revenue from operations increased 22.15% YoY to Rs 586.12 crore in Q3 FY24.
Top